%0 Journal Article %1 dogan2021sarscov2 %A Dogan, Mikail %A Kozhaya, Lina %A Placek, Lindsey %A unter, Courtney %A Yigit, Mesut %A Hardy, Rachel %A Plassmeyer, Matthew %A Coatney, Paige %A Lillard, Kimberleight %A Bukhari, Zaheer %A Kleinberg, Michael %A Hayes, Chelsea %A Arditi, Moshe %A Klapper, Ellen %A Merin, Noah %A Tsan-Tang Liang, Bruce %A Gupta, Raavi %A Alpan, Oral %A Unutmaz, Derya %D 2021 %J Nature, Communications Biology %K CoV-2 antibody assay nautralization plasma %T SARS-CoV-2 specific antibody and neutralization assays revealthe wide range of humoral immune response to virus %U https://www.nature.com/articles/s42003-021-01649-6 %X Development of antibody protection during SARS-CoV-2 infection is a pressing question for public health and for vaccine development. We developed highly sensitive SARS-CoV-2-specific antibody and neutralization assays. SARS-CoV-2 Spike protein or Nucleocapsid protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+ subjects (n = 115) and were absent in the negative controls. Other isotype antibodies (IgA, IgG1-4) were also detected. SARS-CoV-2 neutralization was determined in COVID-19 and convalescent plasma at up to 10,000-fold dilution, using Spike protein pseudotyped lentiviruses, which were also blocked by neutralizing antibodies (NAbs). Hospitalized patients had up to 3000-fold higher antibody and neutralization titers compared to outpatients or convalescent plasma donors. Interestingly, some COVID-19 patients also possessed NAbs against SARS-CoV Spike protein pseudovirus. Together these results demonstrate the high specificity and sensitivity of our assays, which may impact understanding the quality or duration of the antibody response during COVID-19 and in determining the effectiveness of potential vaccines.

@article{dogan2021sarscov2, abstract = {Development of antibody protection during SARS-CoV-2 infection is a pressing question for public health and for vaccine development. We developed highly sensitive SARS-CoV-2-specific antibody and neutralization assays. SARS-CoV-2 Spike protein or Nucleocapsid protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+ subjects (n = 115) and were absent in the negative controls. Other isotype antibodies (IgA, IgG1-4) were also detected. SARS-CoV-2 neutralization was determined in COVID-19 and convalescent plasma at up to 10,000-fold dilution, using Spike protein pseudotyped lentiviruses, which were also blocked by neutralizing antibodies (NAbs). Hospitalized patients had up to 3000-fold higher antibody and neutralization titers compared to outpatients or convalescent plasma donors. Interestingly, some COVID-19 patients also possessed NAbs against SARS-CoV Spike protein pseudovirus. Together these results demonstrate the high specificity and sensitivity of our assays, which may impact understanding the quality or duration of the antibody response during COVID-19 and in determining the effectiveness of potential vaccines.}, added-at = {2021-08-14T15:20:33.000+0200}, author = {Dogan, Mikail and Kozhaya, Lina and Placek, Lindsey and unter, Courtney and Yigit, Mesut and Hardy, Rachel and Plassmeyer, Matthew and Coatney, Paige and Lillard, Kimberleight and Bukhari, Zaheer and Kleinberg, Michael and Hayes, Chelsea and Arditi, Moshe and Klapper, Ellen and Merin, Noah and Tsan-Tang Liang, Bruce and Gupta, Raavi and Alpan, Oral and Unutmaz, Derya}, biburl = {https://www.bibsonomy.org/bibtex/243bd8f6fddb30562f012ea4a539bf2ea/bellao}, interhash = {217a9d483c39b19564660c0420618687}, intrahash = {43bd8f6fddb30562f012ea4a539bf2ea}, journal = {Nature, Communications Biology}, keywords = {CoV-2 antibody assay nautralization plasma}, language = {English}, month = jan, timestamp = {2022-04-24T11:20:55.000+0200}, title = {SARS-CoV-2 specific antibody and neutralization assays revealthe wide range of humoral immune response to virus}, url = {https://www.nature.com/articles/s42003-021-01649-6}, year = {2021 } }